证券代码：688580 证券简称：伟思医疗 公告编号：2025-034 南京伟思医疗科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （二） 股东大会召集人：董事会 1 股东大会召开日期：2025年9月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 15 日 11 点 00 分 召开地点：南京市雨花台区宁双路 19 号 H 栋公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-029 南京伟思医疗科技股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第五次 会议通知于 2025 年 8 月 15 日以书面方式向全体董事发出。会议于 2025 年 8 月 27 日以现场结合通讯方式在公司会议室召开。 本次会议由董事长王志愚先生召集并主持，会议应到董事 7 人，实到董事 7 人，公司全体监事和高级管理人员列席了会议。本次会议的召集、召开程序符合 《中华人民共和国公司法》等相关法律、行政法规、规范性文件及《南京伟思医 疗科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 经审议，董事会认为：公司 2025 年半年度报告的编制和审议程序符合相关 法律法规及《公司章程》等内部规章制度的规定；公司 2025 年半年度报 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2025, representing a 20% increase compared to the same period last year[1]. - The company achieved operating revenue of CNY 210,453,384.34 for the first half of the year, representing a year-on-year increase of 9.85%[22]. - The total profit for the period was CNY 76,536,081.44, which is a 44.55% increase compared to the same period last year[22]. - Net profit attributable to shareholders reached CNY 69,324,242.51, marking a 39.71% year-on-year growth[23]. - The net cash flow from operating activities was CNY 64,784,963.71, reflecting a significant increase of 101.53% compared to the previous year[23]. - The company's total assets at the end of the reporting period were CNY 1,781,006,964.68, a decrease of 2.16% from the previous year[23]. - Basic earnings per share increased to CNY 0.72, up 38.46% from CNY 0.52 in the same period last year[24]. - The company's R&D expenditure accounted for 12.49% of operating revenue, down 6.09 percentage points from the previous year[24]. - The company’s net profit excluding non-recurring gains and losses was CNY 63.57 million, reflecting a year-on-year increase of 46.30%[123]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[1]. - The company has established partnerships with three new healthcare providers to enhance service delivery and patient reach[1]. - The company is actively involved in research and development of innovative treatment methods, including transcranial magnetic stimulation (TMS) and surface electromyography (sEMG) technologies[13]. - The company is focusing on advanced technologies such as multimodal solutions with transcranial magnetic stimulation and AI-based personalized parameter algorithms to expand industry development[45]. - The company aims to enhance its R&D innovation engine and accelerate the development of a multidimensional product matrix, focusing on high-end equipment localization and comprehensive rehabilitation clinical solutions[54]. - The company is accelerating international expansion, participating in key international exhibitions, which has garnered positive market feedback[84]. Product Development and Innovation - New product launches include an advanced rehabilitation device that is projected to generate an additional RMB 100 million in revenue by the end of 2025[1]. - The introduction of new products such as the MyOnyx series, which is marketed as a biofeedback device, indicates a strategic expansion in the medical technology sector[14]. - The company is actively developing high-quality rehabilitation products and solutions, focusing on areas such as pelvic floor rehabilitation and neurological rehabilitation[30]. - The company has developed a comprehensive children's rehabilitation solution targeting conditions such as autism and ADHD[74]. - The company has launched a new MRI-guided transcranial magnetic stimulation robot, with 12 patents applied for, enhancing treatment precision for conditions like depression[98]. - The company has successfully launched a new line of picosecond laser devices, achieving a breakthrough in technology and obtaining the necessary regulatory certifications[113]. Research and Development - Research and development expenses increased by 30%, totaling RMB 50 million, focusing on innovative rehabilitation technologies[1]. - The company holds a total of 217 authorized patents, including 60 invention patents and 101 utility model patents[70]. - The company has established a research and development center centered on six core technology platforms, supporting rapid business growth and innovation in rehabilitation medical devices[96]. - The company is focusing on optimizing its smart cloud product functions to enhance user engagement and reduce operational costs[115]. - The company is actively researching new forms of radio frequency technology for pelvic floor diseases to enhance treatment efficacy and patient comfort[102]. Risk Management and Compliance - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company has established a professional regulatory department to ensure compliance with new policies and regulations, mitigating operational risks associated with policy changes[122]. - The company is closely monitoring industry regulations and policies to adapt its strategies accordingly, ensuring compliance and minimizing risks[121]. - The company is addressing core competitiveness risks by ensuring continuous technological upgrades and aligning R&D with market demands[118]. Corporate Governance and Shareholder Relations - The company has implemented a stock incentive plan, with the first grant of restricted stock set at 22 RMB per share for 87,200 shares[139]. - The company has established measures to resolve related party transactions involving major shareholders and board members, effective from December 10, 2019[148]. - The company has committed to improving investor rights protection measures in accordance with regulatory requirements[193]. - The company emphasizes the importance of protecting the legitimate rights of minority investors in its operational commitments[193]. - The company will ensure compliance with the "Nanjing Weisi Medical Technology Co., Ltd. Stock Price Stabilization Plan" for three years post-listing[178]. Industry Trends and Market Demand - The medical device industry in China is experiencing structural changes, with significant market demand driven by policies promoting high-quality development and the establishment of a three-tiered medical system[40]. - The demand for rehabilitation medical devices is expected to continue growing due to factors such as an aging population and increasing chronic disease prevalence[42]. - The intelligent rehabilitation training equipment market is driven by technological breakthroughs, policy incentives, and increasing consumer health awareness[64]. - The rehabilitation medical device sector is growing rapidly, driven by an increasing demand from populations needing rehabilitation services, including postpartum women and elderly patients[42].

上海众辰电子科技股份有限公司 累积投票制实施细则 上海众辰电子科技股份有限公司 第一章 总 则 第一条 为规范上海众辰电子科技股份有限公司（以下简称"公司"）董事、 监事的选举，保证公司所有股东充分行使权利，维护中小股东的合法权益，根据 《上市公司治理准则》《上海证券交易所股票上市规则》等法律、法规、规范性 文件及《上海众辰电子科技股份有限公司章程》（以下简称"公司章程"）的有 关规定，制定本细则。 第五条 公司依照公司章程规定的方式和程序确定董事候选人，确保选举的 公开、公平、公正。 第二条 公司股东会就选举两名以上董事进行表决时，实行累积投票制。 前款所称累积投票制是指股东会选举董事时，每一股份拥有与应选董事人数 相同的表决权，股东拥有的表决权可以集中使用。 第三条 本细则适用于公司董事（包括独立董事）的选举。由职工代表担任 的董事由公司职工代表大会以民主形式选举产生或更换，不适用于本实施细则的 相关规定。 第四条 公司通过累积投票制选举产生的董事，其任期不实施交错任期制， 即届中因缺额而补选的董事任期为本届余任期限，不跨届任职。 第二章 董事候选人的提名 第六条 董事候选人提名的方式为： （一）董事候选 ...

上海众辰电子科技股份有限公司 薪酬与考核委员会工作细则 上海众辰科技电子股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总 则 第一条 为完善上海众辰电子科技股份有限公司（以下简称"公司"）法人 治理结构，制订科学、有效的薪酬管理制度，根据《上市公司治理准则》和《上 海众辰电子科技股份有限公司章程》（以下简称"《公司章程》"）及其他有关规定， 公司特设立薪酬与考核委员会，并制定本工作细则。 第二条 薪酬与考核委员会是设在董事会下的一个专门委员会。 第三条 薪酬与考核委员会必须遵守公司章程，在董事会授权的范围内独 立行使职权，并直接向董事会负责。 第四条 薪酬与考核委员会隶属于董事会，是董事会的专门参谋机构，对 董事会负责；薪酬与考核委员会也是公司的人力资源部有关重大问题的议事机 构。 第五条 薪酬与考核委员会应当保证公司有关薪酬与考核的重大政策在形 成决议前已得到了充分、专业、科学并合乎规范程序的论证。 第二章 薪酬与考核委员会的产生与组成 第六条 薪酬与考核委员会由三名委员组成，设主任委员一名。 第七条 薪酬与考核委员会委员由董事组成，其中独立董事委员不少于委 员会人数的二分之一。主任委员由独立董事担 ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 最近三个交易日，20日-22日，伟思医疗分别获融资买入0.36亿元、0.22亿元、0.15亿元。 8月22日，沪深两融数据显示，伟思医疗获融资买入额0.15亿元，居两市第1279位，当日融资偿还额0.22 亿元，净卖出649.73万元。 ...

Company Overview - Weisi Medical's closing price on August 22 was 54.72 CNY, with an increase of 1.11%, resulting in a rolling price-to-earnings (PE) ratio of 46.20 times and a total market capitalization of 5.241 billion CNY [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices, including magnetic stimulation, electrical stimulation, electrophysiology, consumables and accessories, and laser radiofrequency products [1] Financial Performance - For the first quarter of 2025, Weisi Medical reported a revenue of 95.9127 million CNY, representing a year-on-year increase of 9.40% [1] - The net profit for the same period was 33.2201 million CNY, showing a significant year-on-year growth of 52.71%, with a sales gross margin of 66.65% [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 CNY and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, positioning Weisi Medical at the 85th rank within the industry [2] - The industry average market capitalization is 12.243 billion CNY, while Weisi Medical's market cap is 5.241 billion CNY [2]

Group 1 - The core point of the news is that Weisi Medical has seen significant financing activity, with a net buy of 2.96 million yuan on August 21, 2023, following recent trends in financing purchases [1] - Over the last three trading days from August 19 to August 21, Weisi Medical received financing purchases of 3.6 million yuan, 3.6 million yuan, and 2.2 million yuan respectively, indicating a consistent interest from investors [1] - On the short selling side, there were no shares sold or net sold on the same day, suggesting a lack of bearish sentiment towards the stock [1]

Company Overview - Weisi Medical's closing price on August 20 was 55.88 yuan, down 2.82%, with a rolling PE ratio of 47.18 times and a total market value of 5.352 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 59.32 times and a median of 39.97 times, placing Weisi Medical at the 83rd position in the industry ranking [1] Shareholder Information - As of March 31, 2025, Weisi Medical had 5,933 shareholders, an increase of 637 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Performance - In the first quarter of 2025, Weisi Medical reported revenue of 95.9127 million yuan, a year-on-year increase of 9.40%, and a net profit of 33.2201 million yuan, reflecting a year-on-year growth of 52.71%, with a gross profit margin of 66.65% [1] Industry Comparison - The PE ratios for other companies in the medical device sector range from 11.61 to 20.96, with Weisi Medical's PE ratio being higher than the industry average and median [2]

Core Insights - The brain-computer interface (BCI) industry is expected to accelerate its development due to proactive policy support from the government, with key technological breakthroughs anticipated by 2027 [1][2] - The global BCI market in the medical application sector is projected to reach $40 billion by 2030 and exceed $145 billion by 2040, indicating significant growth potential [1][5] Policy Support - The Ministry of Industry and Information Technology and six other departments issued guidelines to promote innovation in the BCI industry, aiming for breakthroughs in key technologies by 2027 and establishing advanced technical, industrial, and standard systems [2] - The guidelines also emphasize the application of BCI products across various sectors, including industrial manufacturing, healthcare, and consumer life, with plans to create 2 to 3 industrial development clusters [2] Payment Standardization - The National Healthcare Security Administration released a trial guideline for pricing projects related to neurological medical services, specifically establishing pricing for invasive BCI procedures [3] - Provinces such as Hubei, Zhejiang, and Jiangsu have set BCI medical pricing, addressing previous ambiguities in pricing standards and facilitating the adoption of BCI technologies in healthcare [3] Investment Activity - There has been a notable increase in investment activity within the BCI sector, with over 1,000 disclosed financing transactions and nearly 400 companies receiving investments totaling close to $10 billion as of April 2025 [4] - This influx of capital is expected to accelerate technological innovation and product iteration in the BCI field [4] Investment Recommendations - Companies such as Weisi Medical (688580.SH) are recommended for investment, with additional attention suggested for Xiangyu Medical (688626.SH), Mylande (688273.SH), and others [5]